(Q28369091)

2

0 references

M C Bélanger

3

0 references

A Ravindran

4

0 references

D Bakish

5

0 references

L Beauclair

6

0 references

P Morris

7

0 references

N P Vasavan Nair

8

0 references

R Manchanda

9

0 references

R Reesal

10

0 references

R Remick

11

0 references

M C O'Neill

Journal of Affective Disorders

12

0 references

language of work or name

English

0 references

publication date

July 1999

0 references

published in

0 references

volume

54

0 references

issue

1-2

0 references

page(s)

39-48

0 references

cites work

A double-blind multicentre study of paroxetine and amitriptyline in depressed outpatients. Italian Paroxetine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900188-8

7 January 2021

Effect of acute and chronic fluoxetine on extracellular dopamine levels in the caudate-putamen and nucleus accumbens of rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900188-8

7 January 2021

A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900188-8

7 January 2021

A Comparison of Paroxetine, Imipramine and Placebo in Depressed Out-patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900188-8

7 January 2021

Changes in dopamine metabolism in rat forebrain regions after cessation of long-term fluoxetine treatment: relationship with brain concentrations of fluoxetine and norfluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900188-8

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900188-8

7 January 2021

Comparison between zimeldine and amitriptyline of efficacy and adverse symptoms--a combined analysis of four British clinical trials in depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900188-8

7 January 2021

Movement Disorders Associated With the Serotonin Selective Reuptake Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900188-8

7 January 2021

Paroxetine in the treatment of depression. A double-blind multicenter study versus mianserin

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900188-8

7 January 2021

Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900188-8

7 January 2021

Fluoxetine vs. clomipramine in depressed patients: a controlled multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900188-8

7 January 2021

Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900188-8

7 January 2021

Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2898%2900188-8

7 January 2021